$CSPCY News
Last published 3y ago
- 3y agoCSPCYELEVElevation Oncology Highlights First-in-Human Phase 1 SYSA1801 (EO-3021) Clinical Data to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023PR NewswireInitial data showed promising signs of efficacy, including a 47.1% ORR in patients with resistant/refractory gastric cancer expressing Claudin 18.2, with a well-tolerated safety profile Elevation Oncology on track to
- 3y agoCSPCYELEVElevation Oncology Highlights Clinical Data for SYSA1801 (EO-3021) to be Presented by Partner CSPC Pharmaceutical Group Limited at ASCO 2023PR NewswireNEW YORK, April 26, 2023 /PRNewswire/ -- Elevation Oncology, Inc. (NASDAQ:ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of
- 3y agoCRBPCSPCYCorbus Pharmaceuticals expands oncology pipeline with the addition of a clinical stage Nectin-4 targeting Antibody Drug Conjugate (ADC)PR NewswireCRB-701 (SYS6002) is designed for improved therapeutic index and to act on a broad range of Nectin-4 expressing tumorsClinical development is underway and will focus on urothelial cancer and other Nectin-4-positive solid
- 4y agoCSPCYELEVElevation Oncology Expands Pipeline through Exclusive Licensing of EO-3021 (SYSA1801), a Clinical Stage Anti-Claudin18.2 Antibody Drug Conjugate, From CSPC Pharmaceutical GroupPR NewswireObtains exclusive worldwide rights (outside Greater China) to develop and commercialize EO-3021 (SYSA1801) Expands pipeline to now include two clinical stage precision oncology candidates for patients with genomically defined solid tumors, including th